Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 1.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Dosimetry of [<sup>177</sup>Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Correlation between Imaging Markers Derived from PET/MRI and Invasive Acquired Biomarkers in Newly Diagnosed Breast Cancer.

Cancers·2023
Same author

Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).

European urology·2023
Same author

Rabbit fever: granulomatous inflammation by Francisella tularensis mimics lung cancer in dual tracer <sup>18</sup>FDG and <sup>68</sup>Ga-FAPI PET/CT.

European journal of nuclear medicine and molecular imaging·2023
Same author

Evaluation of thresholding methods for the quantification of [<sup>68</sup>Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy.

European journal of nuclear medicine and molecular imaging·2023
Same journal

Overall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined <sup>18</sup>F-Flotufolastat PSMA PET and mpMRI.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Erratum.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Live from 2026 SNMMI Annual Meeting in Los Angeles!

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 2.

Catello Somma1, Richard Zimmermann2,3,4, Germo Gericke5

  • 1Seroba Life Sciences Management, Dublin, Ireland; csomma@serobavc.com.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|May 21, 2026
PubMed
Summary
This summary is machine-generated.

Radiopharmaceutical therapy is rapidly expanding, driven by innovation and investment. Key factors for success include platform validation, manufacturing scalability, and clinical adoption strategies for this maturing field.

Keywords:
RPTclinical developmentradionuclide therapyradiopharmaceuticalsreimbursementventure capital

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Experiment Videos

Last Updated: May 23, 2026

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Pharmaceutical Sciences

Background:

  • Radiopharmaceutical therapy is a rapidly growing field with significant scientific and investment momentum.
  • The competitive landscape is shaped by evolving clinical innovation, infrastructure development, and financial investment.

Purpose of the Study:

  • To analyze the dynamics influencing the radiopharmaceutical therapy field.
  • To identify key drivers and challenges for developers and investors.

Main Methods:

  • Analysis of clinical innovation trends.
  • Evaluation of infrastructure build-out and financial investment patterns.
  • Assessment of business models and clinical adoption factors.

Main Results:

  • Platform validation, theranostic integration, and novel isotopes are key to early-stage development and investor interest.
  • Scalable manufacturing and supply chain security are increasingly important for mergers and acquisitions.
  • Distinct business models are emerging, with varying capital and operational considerations.

Conclusions:

  • Clinical adoption depends on improved imaging access, adaptive trials, and reimbursement frameworks.
  • Developers and investors need to focus on differentiation and manufacturing readiness.
  • Navigating the complex radiopharmaceutical therapy landscape requires alignment with regulatory and payer expectations.